Evan W. Warner

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.

Journal: Journal of the National Cancer Institute
Published: March 30, 2023

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes.

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes.

Journal: NPJ precision oncology
Published: November 12, 2022

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.

Journal: Nature cancer
Published: September 30, 2022

Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.

Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.

Journal: Clinical genitourinary cancer
Published: September 16, 2021

Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.

Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.

Journal: European urology oncology
Published: July 13, 2021

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 03, 2021

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2020

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

Journal: European urology
Published: January 20, 2020

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2019

DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.

DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.

Journal: BJU international
Published: October 04, 2018

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Journal: European urology
Published: September 21, 2018

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Journal: Cancer discovery
Published: August 17, 2017
Showing 1-12 of 16

Last Updated: 09/26/2026